CULLINAN THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
CULLINAN THERAPEUTICS, INC. (CGEM) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $22.87 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2023-03-09
- CULLINAN THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2021-03-31 was $22.87M.
- CULLINAN THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2022 was $22.87M, a 0.00% change from fiscal 2021.
- CULLINAN THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2021 was $22.87M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|
| 2022-12-31 | $22.87M 10-K · filed 2023-03-09 | |
| 2021-12-31 | $22.87M 10-K · filed 2022-03-17 | |
| 2021-03-31 | $22.87M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |